Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction
Luciano C. Amado,Anastasios P. Saliaris,Karl H. Schuleri,Marcus St. John,Jin-Sheng Xie,Stephen Cattaneo,Daniel J. Durand,Torin Fitton,Jin Qiang Kuang,Garrick Stewart,Stephanie Lehrke,William W. Baumgartner,Bradley J. Martin,Alan W. Heldman,Joshua M. Hare
DOI: https://doi.org/10.1073/pnas.0504388102
IF: 11.1
2005-08-01
Proceedings of the National Academy of Sciences
Abstract:Although clinical trials of autologous whole bone marrow for cardiac repair demonstrate promising results, many practical and mechanistic issues regarding this therapy remain highly controversial. Here, we report the results of a randomized study of bone-marrow-derived mesenchymal stem cells, administered to pigs, which offer several new insights regarding cellular cardiomyoplasty. First, cells were safely injected by using a percutaneous-injection catheter 3 d after myocardial infarction. Second, cellular transplantation resulted in long-term engraftment, profound reduction in scar formation, and near-normalization of cardiac function. Third, transplanted cells were preprepared from an allogeneic donor and were not rejected, a major practical advance for widespread application of this therapy. Together, these findings demonstrate that the direct injection of cellular grafts into damaged myocardium is safe and effective in the periinfarct period. The direct delivery of cells to necrotic myocardium offers a valuable alternative to intracoronary cell injections, and the use of allogeneic mesenchymal stem cells provides a valuable strategy for cardiac regenerative therapy that avoids the need for preparing autologous cells from the recipient.
multidisciplinary sciences